The Claim

Replacing beta carotene with lutein and zeaxanthin in the AREDS formulation reduces the risk of progression to advanced age-related macular degeneration in adults aged 50–85, as demonstrated by a 18% lower risk (HR 0.82, 95% CI 0.69–0.96; P = .02) compared to the original AREDS formulation containing beta carotene.

Source: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
74score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

In adults aged 50–85, replacing beta carotene with lutein and zeaxanthin in the AREDS supplement reduces the risk of advanced age-related macular degeneration by 18% compared to the original formulation containing beta carotene.

See the scientific wording

Replacing beta carotene with lutein and zeaxanthin in the AREDS formulation may reduce the risk of progression to advanced age-related macular degeneration in adults aged 50–85, as a post-hoc analysis showed a 18% lower risk (HR 0.82, 95% CI 0.69–0.96; P = .02) when comparing lutein + zeaxanthin without beta carotene to the original AREDS formulation with beta carotene.

Why this might work

When lutein and zeaxanthin are taken without beta carotene, they are absorbed better and build up in the back of the eye, where they block harmful blue light and reduce damage from oxygen stress. When beta carotene is present, it blocks lutein and zeaxanthin from being absorbed and reaching the eye, leaving the retina more vulnerable to damage that leads to vision loss.

Verified mechanismbased on 1 study

What the research says

1 study
  1. Study: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.

    For older adults at risk of vision loss, swapping beta carotene for lutein and zeaxanthin in the eye vitamin pill was linked to a lower chance of their vision getting worse — and beta carotene might raise lung cancer risk in former smokers, making the swap even more sensible.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.